HRH2
ENSG00000113749
Target class
GPCR
Chromosome
5
Approved drugs
11
Clinical candidates (approved and in development)
12
- Approved drugs
- 11
- Clinical candidates (approved and in development)
- 12
- Chemical probe available
- Yes
- Target name
- HRH2
- Gene name
- Histamine receptor H2
- Gene symbol
- HRH2
- Protein name
- Histamine H2 receptor (H2R) (HH2R) (Gastric receptor I)
- Gene biotype
- Protein coding
- Gene family
- Histamine receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 45
- Highest tissue expression
- 90.51
- Tissue specificity (Gini)
- 0.634
- Tissue specificity (tau)
- 0.947
- KEGG gene identifiers
- hsa:3274
- Protein interaction confidence
- 0.845667
- Protein interaction partners
- 6
- R-HSA-390650
- R-HSA-418555
- End position
- 175710756
- Start position
- 175657797
- Chromosome
- 5
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein.
- Tissue specificity (tau)
- 0.947317
- Expression inequality (Gini)
- 0.634074
Expression in transcripts per million
- Whole Blood
- 90.51
- Spleen
- 23.98
- Stomach
- 18.85
- Brain - Caudate (basal ganglia)
- 14.5
- Brain - Frontal Cortex (BA9)
- 13.87
Expression in transcripts per million
- Whole Blood90.51
- Spleen23.98
- Stomach18.85
- Brain - Caudate (basal ganglia)14.5
- Brain - Frontal Cortex (BA9)13.87
- Brain - Cortex13.79
- Brain - Nucleus accumbens (basal ganglia)12.88
- Brain - Putamen (basal ganglia)12.07
- Heart - Left Ventricle11.88
- Lung10.21
- Artery - Coronary9.51
- Heart - Atrial Appendage7.45
- Adipose - Subcutaneous7.36
- Artery - Tibial7.17
- Brain - Anterior cingulate cortex (BA24)6.27
- Prostate5.95
- Adipose - Visceral (Omentum)5.87
- Fallopian Tube4.62
- Artery - Aorta4.53
- Nerve - Tibial4.15
- Breast - Mammary Tissue3.9
- Cervix - Ectocervix3.57
- Bladder3.42
- Uterus3.41
- Cervix - Endocervix3.12
And 29 more, listed on the interactive page.
- GO:0006955
- GO:0007187
- GO:0007189
Cellular components
- GO:0005886
- GO:0004969
- GO:0005515
increased heart rate
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased heart rate
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264decreased eating
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased eating
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264Increased, predation
Effects
- Inhibition/Decrease/Downregulation
Studies
- cell-based
Evidence sourcepositive inotropic effect on the human ventricle
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: positive inotropic effect on the human ventricle
- cardiovascular system
- gastrointestinal
Evidence sourcereduction of gastric acid secretion
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: reduction of gastric acid secretion
- cardiovascular system
- gastrointestinal
Evidence sourcedecreased gastric acid secretion
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased gastric acid secretion
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264decreased gastric emptying
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased gastric emptying
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264decreased inflammation
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased inflammation
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264increased drinking
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased drinking
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264Decreased, survival
Effects
- Inhibition/Decrease/Downregulation
Studies
- cell-based
Evidence sourcedecreased blood pressure
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased blood pressure
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264decreased pain
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased pain
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264increased gastric acid secretion
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased gastric acid secretion
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264inflammation
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: inflammation
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264emesis
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: emesis
- cardiovascular system
- gastrointestinal
Evidence sourcestimulation of gastric acid secretion
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: stimulation of gastric acid secretion
- cardiovascular system
- gastrointestinal
Evidence sourceincreased gastric emptying
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased gastric emptying
- immune
- cardiovascular
- gastrointestinal
PubMed 28216264
decreased gastric acid secretion
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: decreased gastric acid secretion
- cardiovascular system
- gastrointestinal
PubMed 23197038positive inotropy
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: positive inotropy
- cardiovascular system
- gastrointestinal
PubMed 23197038increased gastric acid secretion
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: increased gastric acid secretion
- cardiovascular system
- gastrointestinal
PubMed 23197038emesis
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: emesis
- cardiovascular system
- gastrointestinal
PubMed 23197038
Related records
Trials (204)
- : Vascular Function in Health and Disease
- [KJ-INT-002] BE Study
- A Clinico-Bacteriological Study and Effect of Stress Ulcer Prophylaxis on Occurrence of Ventilator Associated Pneumonia
- A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued
- A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued in Subjects in the US Only
- A Comparison of Efficacy of Intravenous Esomeprazole and Ranitidine Treatment of Dyspeptic Pain
- A Crossover Study to Assess the Drug-drug Interaction of Acid Reducing Agent(s) on the Pharmacokinetics of a Single Oral Dose of Lumicitabine (JNJ-64041575) in Healthy Adult Participants
- A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients
- A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants
- A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects
- A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor
- A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer
- A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma
- A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
- A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation
- A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3
- A Relative Bioavailability Study of 20 mg Famotidine Tablets Under Fasting Condition
- A Relative Bioavailability Study of 20 mg Famotidine Tablets Under Fed Condition
- A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers
- A Study Assessing the Drug Levels, Drug Effects, and Safety of BMS-986322 in Healthy Participants
Drugs (15)
- Betazole Histamine H2 receptor agonist
- Betazole hydrochloride Histamine H2 receptor agonist
- Cimetidine Histamine H2 receptor antagonist
- Cimetidine hydrochloride Histamine H2 receptor antagonist
- Ebrotidine Histamine H2 receptor antagonist
- Famotidine Histamine H2 receptor antagonist
- Lafutidine Histamine H2 receptor antagonist
- Methantheline Histamine H2 receptor antagonist
- Methantheline bromide Histamine H2 receptor antagonist
- Nizatidine Histamine H2 receptor antagonist
- Ranitidine Histamine H2 receptor antagonist
- Ranitidine bismuth citrate Histamine H2 receptor antagonist
- Ranitidine hydrochloride Histamine H2 receptor antagonist
- Tolazoline Histamine H2 receptor agonist
- Tolazoline hydrochloride Histamine H2 receptor agonist